ABSTRACT
The placenta is essential for sustaining the growth of the fetus. An increased endoplasmic reticulum (ER) stress has been associated with the impaired placental and fetal development. Cadmium (Cd) is a potent teratogen that caused fetal malformation and growth restriction. The present study investigated the effects of maternal Cd exposure on placental and fetal development. The pregnant mice were intraperitoneally injected with CdCl(2) (4.5mg/kg) on gestational day 9. As expected, maternal Cd exposure during early limb development significantly increased the incidences of forelimb ectrodactyly in fetuses. An obvious impairment in the labyrinth, a highly developed tissue of blood vessels, was observed in placenta of mice treated with CdCl(2). In addition, maternal Cd exposure markedly repressed cell proliferation and increased apoptosis in placenta. An additional experiment showed that maternal Cd exposure significantly upregulated the expression of GRP78, an ER chaperone. Moreover, maternal Cd exposure induced the phosphorylation of placental eIF2α, a downstream molecule of PERK signaling. In addition, maternal Cd exposure significantly increased the level of placental CHOP, another target of PERK signaling, indicating that the unfolded protein response (UPR) signaling was activated in placenta of mice treated with CdCl(2). Interestingly, alpha-phenyl-N-t-butylnitrone, a free radical spin-trapping agent, significantly alleviated Cd-induced placental ER stress and UPR. Taken together, these results suggest that reactive oxygen species (ROS)-mediated ER stress might be involved in Cd-induced impairment on placental and fetal development. Antioxidants may be used as pharmacological agents to protect against Cd-induced fetal malformation and growth restriction.
Subject(s)
Abnormalities, Drug-Induced/etiology , Cadmium/toxicity , Endoplasmic Reticulum Stress/drug effects , Maternal Exposure/adverse effects , Placenta/drug effects , Reactive Oxygen Species/metabolism , Animals , Apoptosis/drug effects , Cyclic N-Oxides/pharmacology , Endoplasmic Reticulum Chaperone BiP , Endoplasmic Reticulum Stress/physiology , Female , Fetal Development/drug effects , Free Radical Scavengers/pharmacology , Histocytochemistry , Male , Mice , Mice, Inbred ICR , Placenta/metabolism , Pregnancy , RNA , Random Allocation , Real-Time Polymerase Chain Reaction , Transcription Factor CHOP/metabolism , Unfolded Protein ResponseABSTRACT
In human and rodent models, endocrine disrupting chemicals (EDCs) interfere with the development of cognition and behaviors. Fenvalerate is a potential EDC. The purpose of this study was to examine whether pubertal fenvalerate exposure altered behavioral development. Mice were orally administered with either vehicle or fenvalerate (7.5 or 30 mg/kg/day) from postnatal day (PND) 28 to PND56. Learning and memory were assessed by Morris Water Maze. Aggressive performance was evaluated by aggressive behavior test. Anxiety-related activities were detected by three tests: open-field, plus-maze and black-white alley. Sensorimotor function was analyzed using beam walking and tightrope. Results found that the impairment for spatial learning and memory was more severe in fenvalerate-exposed female mice than in male mice. In addition, pubertal fenvalerate exposure inhibited aggressive behavior in males. Moreover, pubertal fenvalerate exposure increased anxiety activities in females. Altogether, these results suggest that pubertal fenvalerate exposure impairs spatial cognition and behavioral development in a gender-dependent manner. These findings identify fenvalerate as candidate environmental risk factors for cognitive and behavioral development, especially in the critical period of development.
Subject(s)
Behavior, Animal/drug effects , Cognition/drug effects , Endocrine Disruptors/toxicity , Insecticides/toxicity , Nitriles/toxicity , Pyrethrins/toxicity , Sex Characteristics , Aggression/drug effects , Animals , Anxiety/psychology , Female , Growth/drug effects , Male , Maze Learning/drug effects , Mice , Mice, Inbred ICR , Sexual MaturationABSTRACT
Fenvalerate is a potential endocrine disruptor. Several studies have demonstrated that fenvalerate disrupts testosterone (T) synthesis in testes. T and estradiol (E(2)) are de novo synthesized in the developing brain. Thus, the aim of the present study was to investigate the effects of pubertal fenvalerate exposure on the synthesis of T and E(2) and the expression of androgen receptor (AR) and estrogen receptors (ERs) in cerebral cortex. CD-1 mice were orally administered daily with either vehicle or fenvalerate (7.5 or 30 mg/kg) from postnatal day (PND) 28 to PND56. The level of T and E(2) in cerebral cortex was significantly decreased in males exposed to fenvalerate. In agreement with the decrease in T and E(2) syntheses, the expression of 17ß-HSD, a key enzyme for T synthesis, was significantly reduced in cerebral cortex of fenvalerate-exposed males. Conversely, in females, the expression of 17ß-HSD in cerebral cortex was mildly up-regulated by fenvalerate and the level of T and E(2) was mildly increased. Pubertal fenvalerate exposure had no effect on the expression of StAR, P450(17α) and P450scc, the key enzymes for T synthesis, and P450 aromatase, the key enzyme for E(2) synthesis, in cerebral cortex of males and females. Interestingly, the expression of AR in cerebral cortex was up-regulated in male and female mice exposed to fenvalerate, whereas pubertal fenvalerate exposure did not affect the level of ERα and ERß in cerebral cortex. Taken together, these results suggest that pubertal fenvalerate exposure disrupts T and E(2) synthesis and the expression of AR in cerebral cortex. These changes of steroid status in the developing brain might be deleterious for neurobehavioral development.
